Bavencio Intravenous 200 mg Special Drug Use results Survey (Maintenance following chemotherapy treatment in curatively unresectable urothelial carcinoma)
Latest Information Update: 18 May 2022
At a glance
- Drugs Avelumab (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions
- 09 May 2022 Planned End Date changed from 31 Dec 2023 to 31 Mar 2024.
- 02 Mar 2021 New trial record